Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 2
2008 1
2010 2
2011 5
2012 3
2013 4
2014 10
2015 2
2016 2
2017 6
2018 9
2019 6
2020 2
2021 3
2022 1
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
Modeling of hematologic malignancies by iPS technology.
Arai S, Miyauchi M, Kurokawa M. Arai S, et al. Exp Hematol. 2015 Aug;43(8):654-60. doi: 10.1016/j.exphem.2015.06.006. Epub 2015 Jun 29. Exp Hematol. 2015. PMID: 26135030 Free article. Review.
Nationwide prospective survey of secondary myelofibrosis in Japan: superiority of DIPSS-plus to MYSEC-PM as a survival risk model.
Shide K, Takenaka K, Kitanaka A, Numata A, Kameda T, Yamauchi T, Inagaki A, Mizuno S, Takami A, Ito S, Hagihara M, Usuki K, Maekawa T, Sunami K, Ueda Y, Tsutsui M, Ando M, Komatsu N, Ozawa K, Kurokawa M, Arai S, Mitani K, Akashi K, Shimoda K. Shide K, et al. Among authors: arai s. Blood Cancer J. 2023 Jul 19;13(1):110. doi: 10.1038/s41408-023-00869-9. Blood Cancer J. 2023. PMID: 37463903 Free PMC article. No abstract available.
Real-world clinical characteristics of post-essential thrombocythemia and post-polycythemia vera myelofibrosis.
Shide K, Takenaka K, Kitanaka A, Numata A, Kameda T, Yamauchi T, Inagaki A, Mizuno S, Takami A, Ito S, Hagihara M, Usuki K, Maekawa T, Sunami K, Ueda Y, Tsutsui M, Ando M, Komatsu N, Ozawa K, Kurokawa M, Arai S, Mitani K, Akashi K, Shimoda K. Shide K, et al. Among authors: arai s. Ann Hematol. 2024 Jan;103(1):97-103. doi: 10.1007/s00277-023-05528-4. Epub 2023 Nov 10. Ann Hematol. 2024. PMID: 37946031
CAMK2G is identified as a novel therapeutic target for myelofibrosis.
Miyauchi M, Sasaki K, Kagoya Y, Taoka K, Masamoto Y, Yamazaki S, Arai S, Mizuno H, Kurokawa M. Miyauchi M, et al. Among authors: arai s. Blood Adv. 2022 Mar 8;6(5):1585-1597. doi: 10.1182/bloodadvances.2020003303. Blood Adv. 2022. PMID: 34521112 Free PMC article.
Recurrent CDC25C mutations drive malignant transformation in FPD/AML.
Yoshimi A, Toya T, Kawazu M, Ueno T, Tsukamoto A, Iizuka H, Nakagawa M, Nannya Y, Arai S, Harada H, Usuki K, Hayashi Y, Ito E, Kirito K, Nakajima H, Ichikawa M, Mano H, Kurokawa M. Yoshimi A, et al. Among authors: arai s. Nat Commun. 2014 Aug 27;5:4770. doi: 10.1038/ncomms5770. Nat Commun. 2014. PMID: 25159113 Free article.
54 results